Role of aggressive LDL reduction in patients with coronary heart disease

Southern Medical Journal

Volumn 105, Issue 1, 2012, Pages 48-55

  Benge, Cassandra D ^a   Markley, Brandon ^a   McFarland, Michael Shawn ^a  

^a Tennessee Valley Healthcare System   (United States)

Author keywords

coronary artery disease; hydroxymethylglutaryl coenzyme a reductase inhibitors; lipoproteins; low density lipoprotein

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; CORONARY RISK; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PATIENT CARE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL;

EID: 84855162404     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31823c4242     Document Type: Review

References (30)

1. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360: 7-22.
3. Sheperd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. PROspective study of Pravastatin in the Elderly at Risk. Lancet 2002; 360:1623-1630. (Pubitemid 35379733)
4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
5. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomized controlled trial. Lancet 2003;361:1149-1158. (Pubitemid 36398384)
6. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection TherapyVThrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 2004;350:1495-1504.
7. Grundy SM, Cleeman JI, Bairey Merz NC, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004;110:227-239. (Pubitemid 38924592)
8. Lemons JA, Blazing MA, Wivott ST, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial. JAMA 2004;292:1307-1316. (Pubitemid 39223221)
9. Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. Treating to New Targets (TNT) Investigators. N Engl J Med 2005;352:1425-1435. (Pubitemid 40471450)
10. Pedersen TR, Faegeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The Incremental Decrease in Endpoints Through Aggressive Lipid Lowering (IDEAL). JAMA 2005;294:2437-2445.
11. SEARCH Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12064 survivors of myo-cardial infarction: a double-blind randomized trial. Lancet 2010;376: 1658-1660.
12. Lipitor product information. New York, NY: Parke-Davis, Division of Pfizer Pharmaceuticals; 2009.
13. Crestor product information. Wilmington, DE: Astra-Zeneca Pharmaceuticals; 2011.
14. Livalo product information. Montgomery, AL: Kowa Pharmaceuticals America, Inc, and Lilly USA, LLC; 2011.
15. Zocor product information. Whitehouse Station, NJ: Merck & Co., Inc; 2011.
16. Mevacor product Information. Whitehouse Station, NJ: Merck & Co., Inc; 2010.
17. Pravachol product information. Bristol-Myers Squibb Company. May 2011, Princeton, New Jersey 08543.
18. Lescol product information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
19. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
20. Kausik KR, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndrome: results from the PROVE IT-TIMI 22 Trial. J Am Coll Cardiol 2005;46: 1405-1410. (Pubitemid 41446173)
21. Wivott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy. J Am Coll Cardiol 2005;46: 1411-1416. (Pubitemid 41446174)
22. LaRosa JC, Deedwania PC, Shepherd J, et al. Comparison of 80 mg versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets TNT Trial). Am J Cardiol 2010;105:283-287.
23. Tikkanen MJ, Szarek M, Fayyad R, et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy. Insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) Trial. J Am Coll Cardiol 2009;54:2353-2357.
24. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011;305:2556-2564.
25. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-599.
26. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-767.
27. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. The German Diabetes and Dialysis Study (4D). N Engl J Med 2005;353:238-248. (Pubitemid 41058323)
28. Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376: 1670-1681.
29. Egan A, Colman E. Weighing the benefits of high dose simvastatin against the risk of myopathy. N Engl J Med 2001;365:285-287.
30. Reiner Z, Catapano A, de Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias. The Task Force on the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32: 1769-1818.